血管内动脉瘤修复相比保守治疗在生理上不适合开放手术的患者中提供生存优势并具成本效益
基于1435例心肺运动试验(CPET)评估的腹主动脉瘤患者前瞻性数据库,350例不适合开放手术者接受EVAR或保守治疗,倾向性匹配后各122对。EVAR组中位总生存84个月 vs 保守组30个月(P < .001),增量成本效果比为每获得一个质量调整生命年8023英镑(11644美元)。结论:经CPET筛选不适合开放手术的特定患者中,EVAR较保守治疗提供生存优势且具成本效益。
要点
- 倾向性匹配后EVAR组中位总生存84个月 vs 保守组30个月(P < .001)。
- EVAR组1、3、5年死亡率分别为7%、40%、68%,保守组分别为25%、68%、82%(均P < .001)。
- EVAR增量成本效果比为每质量调整生命年8023英镑(11644美元)。
核心结论
- 基于CPET判定不适合开放手术的特定患者中,EVAR相比保守治疗提供生存优势并具成本效益。
研究设计与样本
- 前瞻性数据库纳入1435例为腹主动脉瘤修复术前评估心肺运动试验(CPET)的患者。
- 350例判定不适合开放手术的患者接受EVAR或保守治疗,采用1:1倾向性匹配纳入年龄、性别、无氧阈和动脉瘤大小比较生存。
- 成本效果分析基于英国国家卫生与临床优化研究所(NICE)腹主动脉瘤治疗临床指南的经济模型。
主要发现
- 倾向性匹配产生EVAR组和保守管理组各122对患者。
- EVAR组中位总生存84个月 vs 保守管理组30个月(P < .001)。
- EVAR组1年、3年、5年死亡率分别为7%、40%、68%,保守管理组分别为25%、68%、82%,均P < .001。
- EVAR增量成本效果比为每获得一个质量调整生命年8023英镑(11644美元),而基于EVAR-2结果的NICE指南中为430602英镑(624967美元)。
关键数值与推荐
- EVAR组中位总生存84个月 vs 保守管理组30个月(P < .001)。
- EVAR组1年死亡率7% vs 保守管理组25%(P < .001)。
- EVAR组3年死亡率40% vs 保守管理组68%(P < .001)。
- EVAR组5年死亡率68% vs 保守管理组82%(P < .001)。
- EVAR增量成本效果比8023英镑(11644美元)每质量调整生命年 vs NICE指南基于EVAR-2结果的430602英镑(624967美元)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The endovascular aneurysm repair-2 (EVAR-2) trial suggested that EVAR in patients unfit for open surgical repair (OSR) failed to provide a significant overall survival advantage compared with conservative management. The aim is to compare survival and cost-effectiveness in patients with poor cardiopulmonary exercise test (CPET) metrics who underwent EVAR or were managed conservatively. METHODS: A prospective database of all CPETs (1435 patients) performed to assess preoperative fitness for abdominal aortic aneurysm repair was maintained. A total of 350 patients deemed unfit for OSR underwent EVAR or were managed conservatively. A 1:1 propensity-matched analysis incorporating age, gender, anaerobic threshold, and aneurysm size was used to compare survival. Cost-effectiveness analysis was based on the economic model for the National Institute for Health and Care Excellence clinical guideline on abdominal aortic aneurysm treatment. RESULTS: Propensity matching produced 122 pairs of patients in the EVAR and conservative management groups. The median overall survival for the EVAR group was significantly longer than that for the conservative management group (84 vs 30 months, P < .001). One-, three-, and five-year mortality in the EVAR group was 7%, 40%, and 68%, respectively, compared with 25%, 68%, and 82% in the conservative management group, all P < .001. The increment cost-effectiveness ratio for EVAR was £8023 (US$11,644) per quality-adjusted life year gained compared with £430,602 (US$624,967) in the National Institute for Health and Care Excellence guideline, which is based on EVAR-2 results. CONCLUSIONS: EVAR offers a survival advantage and is cost-effective in selected patients deemed unfit for OSR based on CPET compared with conservative management.
引用
- Shahin Y, Dixon S, Kerr K, et al. Endovascular aneurysm repair offers a survival advantage and is cost-effective compared with conservative management in patients physiologically unfit for open repair. J Vasc Surg. 2022. PMID: 36152982. doi:10.1016/j.jvs.2022.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。